-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-68498 in Solid Tumor Drug Details:HEC-68498 is under development for the treatment of...
-
Company Insights
Innovation and Patenting activity of Yichang Hec Changjiang Pharmaceutical Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Yichang Hec Changjiang Pharmaceutical Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Company Insights
Innovation and Patenting activity of Guangdong HEC Technology Holding Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Guangdong HEC Technology Holding Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Transitional Cell Cancer (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-88473 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-88473 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-88473 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:HEC-88473 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-68498 in Triple-Negative Breast Cancer (TNBC) Drug Details:HEC-68498 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-585 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-585 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-585 in Interstitial Lung Diseases (Diffuse Parenchymal Lung...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-68498 in Human...
-
Product Insights
NewHepatitis C – Drugs In Development, 2024
Empower your strategies with our Hepatitis C – Drugs In Development, 2024 report and make more profitable business decisions. Hepatitis C is a contagious viral infection affecting the liver. It spreads on contact with infected blood. It may be a mild condition or may be chronic, leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The offspring of...
-
Product Insights
NewThromboembolic Disease – Drugs In Development, 2024
Empower your strategies with our Thromboembolic Disease – Drugs In Development, 2024 report and make more profitable business decisions. Thromboembolism is a condition in which a a thrombus (blood clot) detaches and blocks the blood vessel (embolizes). Venous thromboembolism can lead to two types of conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk factors that contribute to VTE are injury to vein, infection, immobilization, high estrogen, smoking, obesity, age, chronic illness, and blood clotting conditions. Signs and symptoms include...